USD 3.64
(-3.96%)
Year | Total Assets | Total Assets Growth |
---|---|---|
2023 | 86.62 Million USD | 70.35% |
2022 | 50.85 Million USD | 76.61% |
2021 | 28.79 Million USD | 0.0% |
Year | Total Assets | Total Assets Growth |
---|---|---|
2024 Q2 | 197.36 Million USD | -5.98% |
2024 Q1 | 209.92 Million USD | 142.33% |
2023 Q4 | 86.62 Million USD | 62.72% |
2023 Q1 | - USD | -100.0% |
2023 Q3 | 53.23 Million USD | 0.0% |
2023 FY | 86.62 Million USD | 70.35% |
2022 Q4 | 50.85 Million USD | 0.0% |
2022 FY | 50.85 Million USD | 76.61% |
2021 FY | 28.79 Million USD | 0.0% |
Name | Total Assets | Total Assets Difference |
---|---|---|
ADC Therapeutics SA | 354.78 Million USD | 75.583% |
Annovis Bio, Inc. | 10.2 Million USD | -748.607% |
Biohaven Pharmaceutical Holding Company Ltd. | 513.21 Million USD | 83.12% |
Ginkgo Bioworks Holdings, Inc. | 1.66 Billion USD | 94.798% |
Nuvation Bio Inc. | 621.48 Million USD | 86.061% |
Nuvation Bio Inc. | 621.48 Million USD | 86.061% |
Arcus Biosciences, Inc. | 1.09 Billion USD | 92.089% |
Theriva Biologics, Inc. | 60.21 Million USD | -43.874% |
Zymeworks Inc. | 580.88 Million USD | 85.087% |